🚀 VC round data is live in beta, check it out!
Nextbiomedical Co Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nextbiomedical Co and similar public comparables like Tanvex BioPharma, PureTech Health, Absci, DiaMedica and more.
Nextbiomedical Co Overview
About Nextbiomedical Co
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.
Founded
2014
HQ
Employees
N/A
Website
Financials (LTM)
EV
$393M
Nextbiomedical Co Financials
Nextbiomedical Co reported last 12-month revenue of $12M and negative EBITDA of ($34K).
In the same LTM period, Nextbiomedical Co generated $9M in gross profit, ($34K) in EBITDA losses, and had net loss of ($480K).
Revenue (LTM)
Nextbiomedical Co P&L
In the most recent fiscal year, Nextbiomedical Co reported revenue of $7M and EBITDA of $3M.
Nextbiomedical Co expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $12M | XXX | $7M | XXX | XXX | XXX |
| Gross Profit | $9M | XXX | $4M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | ($34K) | XXX | $3M | XXX | XXX | XXX |
| EBITDA Margin | (0%) | XXX | 40% | XXX | XXX | XXX |
| EBIT Margin | (5%) | XXX | (37%) | XXX | XXX | XXX |
| Net Profit | ($480K) | XXX | $2M | XXX | XXX | XXX |
| Net Margin | (4%) | XXX | 31% | XXX | XXX | XXX |
| Net Debt | — | — | $4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nextbiomedical Co Stock Performance
Nextbiomedical Co has current market cap of $406M, and enterprise value of $393M.
Market Cap Evolution
Nextbiomedical Co's stock price is $49.95.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $393M | $406M | (1.3%) | XXX | XXX | XXX | $0.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNextbiomedical Co Valuation Multiples
Nextbiomedical Co trades at 31.9x EV/Revenue multiple, and (11502.8x) EV/EBITDA.
EV / Revenue (LTM)
Nextbiomedical Co Financial Valuation Multiples
As of March 7, 2026, Nextbiomedical Co has market cap of $406M and EV of $393M.
Equity research analysts estimate Nextbiomedical Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nextbiomedical Co has a P/E ratio of (845.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $406M | XXX | $406M | XXX | XXX | XXX |
| EV (current) | $393M | XXX | $393M | XXX | XXX | XXX |
| EV/Revenue | 31.9x | XXX | 60.1x | XXX | XXX | XXX |
| EV/EBITDA | (11502.8x) | XXX | 150.2x | XXX | XXX | XXX |
| EV/EBIT | (604.3x) | XXX | (162.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 45.7x | XXX | 99.9x | XXX | XXX | XXX |
| P/E | (845.1x) | XXX | 203.5x | XXX | XXX | XXX |
| EV/FCF | 344.3x | XXX | (354.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nextbiomedical Co Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nextbiomedical Co Margins & Growth Rates
Nextbiomedical Co's revenue in the last 12 month grew by 49%.
Nextbiomedical Co's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nextbiomedical Co's rule of X is 123% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Nextbiomedical Co Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 49% | XXX | 73% | XXX | XXX | XXX |
| EBITDA Margin | (0%) | XXX | 40% | XXX | XXX | XXX |
| EBITDA Growth | (2330%) | XXX | (99%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 123% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 44% | XXX | 69% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 97% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nextbiomedical Co Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tanvex BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| PureTech Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Absci | XXX | XXX | XXX | XXX | XXX | XXX |
| DiaMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Upstream Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nextbiomedical Co M&A Activity
Nextbiomedical Co acquired XXX companies to date.
Last acquisition by Nextbiomedical Co was on XXXXXXXX, XXXXX. Nextbiomedical Co acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nextbiomedical Co
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNextbiomedical Co Investment Activity
Nextbiomedical Co invested in XXX companies to date.
Nextbiomedical Co made its latest investment on XXXXXXXX, XXXXX. Nextbiomedical Co invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nextbiomedical Co
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nextbiomedical Co
| When was Nextbiomedical Co founded? | Nextbiomedical Co was founded in 2014. |
| Where is Nextbiomedical Co headquartered? | Nextbiomedical Co is headquartered in South Korea. |
| Is Nextbiomedical Co publicly listed? | Yes, Nextbiomedical Co is a public company listed on Korea Exchange. |
| What is the stock symbol of Nextbiomedical Co? | Nextbiomedical Co trades under 389650 ticker. |
| When did Nextbiomedical Co go public? | Nextbiomedical Co went public in 2024. |
| Who are competitors of Nextbiomedical Co? | Nextbiomedical Co main competitors are Tanvex BioPharma, PureTech Health, Absci, DiaMedica. |
| What is the current market cap of Nextbiomedical Co? | Nextbiomedical Co's current market cap is $406M. |
| What is the current revenue of Nextbiomedical Co? | Nextbiomedical Co's last 12 months revenue is $12M. |
| What is the current revenue growth of Nextbiomedical Co? | Nextbiomedical Co revenue growth (NTM/LTM) is 49%. |
| What is the current EV/Revenue multiple of Nextbiomedical Co? | Current revenue multiple of Nextbiomedical Co is 31.9x. |
| Is Nextbiomedical Co profitable? | No, Nextbiomedical Co is not profitable. |
| What is the current EBITDA of Nextbiomedical Co? | Nextbiomedical Co has negative EBITDA and is not profitable. |
| What is Nextbiomedical Co's EBITDA margin? | Nextbiomedical Co's last 12 months EBITDA margin is (0%). |
| What is the current EV/EBITDA multiple of Nextbiomedical Co? | Current EBITDA multiple of Nextbiomedical Co is (11502.8x). |
| What is the current FCF of Nextbiomedical Co? | Nextbiomedical Co's last 12 months FCF is $1M. |
| What is Nextbiomedical Co's FCF margin? | Nextbiomedical Co's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Nextbiomedical Co? | Current FCF multiple of Nextbiomedical Co is 344.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.